Apeiron announces start of phase I trail with cellular anti cancer therapy
Apeiron Biologics AG announced that a first patient has been treated as part of a phase I clinical trial with Apeiron’s individual cellular therapy APN401. The investigator-initiated trial is performed at Wake Forest Baptist Medical Center (WFBMC) led by Pierre L. Triozzi, professor of internal medicine at WFBMC’s Comprehensive Cancer Center, North Carolina, USA.
The trial studies the safety, tolerability and optimal dose of autologous, peripheral immune cells silenced ex-vivo for the Cbl-b gene, a completely novel approach to support the immune system’s ability to fight cancer via checkpoint blockade.
“There are factors in immune cells that hamper their ability to efficiently kill cancer cells. Achieving a so-called ‘checkpoint blockade’ by treating certain blood derived immune cells ex-vivo with a small interfering ribonucleic acid (siRNA) to silence the Cbl-b gene helps those cells to more efficiently kill cancer cells after re-infusion," said Pierre L. Triozzi. “Such activation of the immune system could in principle be applied for treatment of any type of cancer, and also in combination with other immunotherapies such as other checkpoint blockades or cancer vaccination approaches,” he added.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
